<DOC>
	<DOCNO>NCT02898610</DOCNO>
	<brief_summary>This study evaluate use Colchicine adult 40 year age suffer ischaemic stroke transient ischaemic attack NOT cause cardiac embolism define cause . Patients randomise 0.5 mg/day Colchicine plus usual care , usual care alone . To investigate efficacy low dose colchicine ( 0.5mg/day ) plus usual care ( defined antiplatelet , lipid-lowering , antihypertensive treatment , appropriate lifestyle advice ) compare usual care alone prevent non-fatal recurrent ischaemic stroke , myocardial infarction , cardiac arrest , hospitalization unstable angina vascular death ischaemic stroke transient ischaemic attack ( TIA ) cause cardiac embolism define cause unrelated atherosclerosis</brief_summary>
	<brief_title>Colchicine Prevention Vascular Inflammation Non-cardio Embolic Stroke</brief_title>
	<detailed_description>Inflammation key pathophysiological contributor unstable atherosclerotic plaque thrombo-embolic event , stroke , myocardial infarction , vascular death . Internationally , clinical trial target atherosclerotic inflammation patient coronary disease use methotrexate , colchicine , canukinumab . Aims : The primary aim compare low-dose colchicine ( 0.5mg/day ) plus usual care , usual care alone , prevent non-fatal recurrent ischaemic stroke coronary event vascular death non-severe , noncardioembolic TIA/stroke . Secondary objective investigate safety low-dose colchicine , efficacy component primary outcome , fatal non-fatal event , disable non-disabling stroke , effect modification prespecified subgroup , impact direct health care cost , adjust quality-adjusted life year .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>1 . Written inform consent consistent ICHGCP guideline local law sign prior trialrelated procedure . 2 . Age 40 year great 3 . Either , ischaemic stroke without major disability ( modify Rankin score 3 less ) highrisk TIA 4 . Qualifying stroke/TIA probably cause large artery stenosis , small artery occlusion ( lacunar stroke ) , cryptogenic embolism , cardiac embolism define stroke mechanism deem unlikely opinion treat physician . 5 . GFRgreater equal 50 ml/min . 6 . In opinion treat physician , patient medicallystable , capable participate randomised trial , willing attend followup . 1 . Cardioembolic stroke/TIA , probably cause identify atrial fibrillation ( permanent paroxysmal ) , opinion treat physician . 2 . Cardioembolic stroke/TIA probably cause identified cardiac source ( intracardiac thrombus , endocarditis , metallic heart valve , low ejection fraction &lt; 30 % ) , opinion treat physician . 3 . Stroke/TIA cause dissection , endocarditis , paradoxical embolism , drug use , venous thrombosis , within 48 hour aftercarotid cardiac surgery , hypercoagulability state , migraine , inherit cerebrovascular disorder ( eg . Fabry 's disease , CADASIL ) , opinion treat physician . 4 . History myopathy myalgia raise creatine kinase ( CK ) statin therapy . 5 . Blood dyscrasia define anaemia ( haemoglobin &lt; 10g/dL ) , thrombocytopenia ( platelet count &lt; 150 x109/L ) leucopenia ( white cell count &lt; 4 x109/L ) randomisation . 6 . Impaired hepatic function ( transaminase great twice upper limit normal ) randomisation . 7 . Concurrent treatment moderate strong CYP3A4 inhibitor ( clarithromycin , erythromycin , telithromycin , macrolide antibiotic , ketoconazole , itraconazole , voriconazole , ritonavir , atazanavir , indinavir , HIV protease inhibitor , verapamil , diltiazem , quinidine , digoxin , disulfiram ) Pgp inhibitor ( cyclosporine ) randomisation . 8 . Symptomatic peripheral neuropathy preexist progressive neuromuscular disease 9 . Inflammatory bowel disease ( Crohn 's ulcerative colitis ) chronic diarrhoea . 9 . Dementia , sufficient impair independence basic activity daily live . 10 . Active malignancy , know hepatitis B C , HIV infection prior qualify stroke/TIA . 11 . Impaired swallow prevent oral administration study medication . 12 . History poor medication compliance . 13 . Unlikely comply study procedure followup visit due severe fatal comorbid illness factor ( eg . inability travel follow visit ) , opinion randomise physician . 14 . Pregnancy , breastfeeding , premenopausal woman 15 . Patient concurrently participate another clinical trial investigational drug device , use investigational drug within 30 day 5 halflives Screening visit ( whichever longer ) 16 . Known allergy sensitivity colchicine .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>